SHARE

AstraZeneca to buy EsoBiotec

The drug company is set to acquire Belgium-based EsoBiotec, a leader in vivo cell therapy, in a deal worth up to $1bn. This will include an initial payment of $425m on the deal closing, and up to $575m based on development and regulatory milestones.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.